MCID: CRV043
MIFTS: 42

Cervical Dystonia

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Cervical Dystonia

MalaCards integrated aliases for Cervical Dystonia:

Name: Cervical Dystonia 12 52 36 15
Spasmodic Torticollis 12 74 52 32

Classifications:



External Ids:

Disease Ontology 12 DOID:0050840
KEGG 36 H01608
ICD10 32 G24.3

Summaries for Cervical Dystonia

NIH Rare Diseases : 52 Cervical dystonia is a neurological condition characterized by excessive pulling of the muscles of the neck and shoulder resulting in abnormal movements of the head (dystonia). Most commonly, the head turns to one side or the other. Tilting sideways, or to the back or front may also occur. The turning or tilting movements may be accompanied by shaking movement (tremor ) and/or soreness of the muscles of the neck and shoulders. Cervical dystonia can occur at any age, but most cases occur in middle age. It often begins slowly and usually reaches a plateau over a few months or years. The cause of cervical dystonia is often unknown. In some cases there is a family history . Several genes have been associated with cervical dystonia, including GNAL , THAP1 , CIZ1 , and ANO3 . Other cases may be linked to an underlying disease (e.g. Parkinson disease), neck trauma, or certain medications. Treatment may include local injections of botulinum toxin , pain medications, benzodiazepines (anti-anxiety medications), anticholinergics , physical therapy , or surgery.

MalaCards based summary : Cervical Dystonia, also known as spasmodic torticollis, is related to dystonia 23 and dystonia 24. An important gene associated with Cervical Dystonia is CIZ1 (CDKN1A Interacting Zinc Finger Protein 1), and among its related pathways/superpathways are Methylphenidate Pathway, Pharmacodynamics and Folate biosynthesis. The drugs Acetylcholine and rimabotulinumtoxinB have been mentioned in the context of this disorder. Affiliated tissues include brain, globus pallidus and subthalamic nucleus, and related phenotypes are behavior/neurological and nervous system

Disease Ontology : 12 A focal dystonia that is characterized by simultaneous contraction of the agonist and antagonist muscles that control the position of the head contracting during dystonic movement which causes the neck to involuntarily turn to the left, right, upwards, and/or downwards.

KEGG : 36 Cervical dystonia (CD), formerly referred to as spasmodic torticollis, is a condition characterized by simultaneous and sustained contractions of both agonist and antagonist muscles of the neck, which frequently result in abnormal movements or postures. CD is considered a form of primary adult-onset focal dystonia. The majority of patients complain of pain, which is not a common feature of other focal dystonias. Head rotation is common, but head tilt, neck extension, and flexionmay also occur, often in combination. The pathogenesis of primary CD is unclear. Patients with secondary CD may have an abnormal birth or developmental history, exposure to drugs known to cause dystonia (tardive dystonia), or neurological illness. Intramuscular injections of botulinum toxin (BoNT), have been shown to be efficacious and well tolerated when used to treat CD, and are therefore recommended as first-line therapy by current treatment guidelines.

Wikipedia : 74 Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to... more...

Related Diseases for Cervical Dystonia

Diseases related to Cervical Dystonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 dystonia 23 33.4 CIZ1 ANO3
2 dystonia 24 32.8 THAP1 GNAL ANO3
3 torsion dystonia 4 32.1 GNAL CIZ1 ANO3
4 torticollis 31.9 TOR1A CIZ1
5 lymphatic malformation 5 31.8 TOR1A THAP1 SGCE OMD GCH1
6 spasmodic dysphonia 30.8 TOR1A THAP1
7 dystonia 3, torsion, x-linked 30.8 TOR1A THAP1 SGCE PRKRA GCH1 ATP1A3
8 dystonia 11, myoclonic 30.5 TOR1A THAP1 SGCE JRK GNAL GCH1
9 neurotic disorder 30.2 TH BDNF
10 gilles de la tourette syndrome 30.1 TH SGCE DRD5 BDNF
11 obsessive-compulsive disorder 29.7 TOR1A SGCE GCH1 BDNF
12 isolated dystonia 29.7 TOR1A THAP1 GNAL GCH1 ANO3
13 hereditary dystonia 29.6 TH GCH1 ATP1A3 ANO3
14 parkinson disease, late-onset 29.6 TOR1A TH SPR GCH1 DRD5 BDNF
15 dystonia 1, torsion, autosomal dominant 29.6 TOR1A THAP1 SGCE GNAL GCH1 CIZ1
16 choreatic disease 29.4 SGCE JRK GCH1 DRD5 BDNF
17 oculogyric crisis 29.4 SPR GCH1 DRD5 ATP1A3
18 focal hand dystonia 28.6 TOR1A THAP1 SGCE OR4X2 JRK GNAL
19 oromandibular dystonia 28.4 TOR1A THAP1 SGCE OMD GCH1 CIZ1
20 dystonia 28.3 TOR1A THAP1 TH SPR SGCE PRKRA
21 dystonia 12 28.1 TOR1A THAP1 SGCE PRKRA GNAL GCH1
22 segmental dystonia 28.0 TOR1A THAP1 SGCE PRKRA GNAL GCH1
23 blepharospasm 27.9 TOR1A THAP1 SGCE OMD JRK GNAL
24 focal dystonia 27.6 TOR1A THAP1 SGCE PRKRA OMD JRK
25 movement disease 27.5 TOR1A THAP1 TH SGCE PRKRA OMD
26 spasmodic dystonia 27.1 TOR1A THAP1 SGCE PRKRA OMD JRK
27 leukoencephalopathy with dystonia and motor neuropathy 11.6
28 dyt-gnal 11.6
29 dystonia 7, torsion 11.5
30 dyt-thap1 11.5
31 dystonia 4, torsion, autosomal dominant 11.2
32 klippel-feil syndrome 11.2
33 gtp cyclohydrolase 1-deficient dopa-responsive dystonia 11.2
34 tremor 10.8
35 dysphagia 10.7
36 dystonia, focal, task-specific 10.6
37 benign paroxysmal torticollis of infancy 10.6
38 ataxia and polyneuropathy, adult-onset 10.4
39 essential tremor 10.4
40 neonatal hypoxic and ischemic brain injury 10.4 TH BDNF
41 facial spasm 10.3
42 severe combined immunodeficiency 10.3
43 hyperphenylalaninemia, bh4-deficient, b 10.3 TH GCH1
44 segawa syndrome, autosomal recessive 10.3 TH GCH1
45 dystonia 6, torsion 10.3 THAP1 CIZ1
46 autosomal dominant cerebellar ataxia 10.3
47 social phobia 10.2
48 pica disease 10.2
49 vestibular nystagmus 10.2
50 thoracic outlet syndrome 10.2

Graphical network of the top 20 diseases related to Cervical Dystonia:



Diseases related to Cervical Dystonia

Symptoms & Phenotypes for Cervical Dystonia

MGI Mouse Phenotypes related to Cervical Dystonia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.83 ATM ATP1A3 BDNF CDIP1 CIZ1 DRD5
2 nervous system MP:0003631 9.4 ATM ATP1A3 BDNF DRD5 GCH1 NALCN

Drugs & Therapeutics for Cervical Dystonia

Drugs for Cervical Dystonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2 rimabotulinumtoxinB Phase 4
3 incobotulinumtoxinA Phase 4
4 abobotulinumtoxinA Phase 4
5 Botulinum Toxins Phase 4
6 Botulinum Toxins, Type A Phase 4
7 Cholinergic Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 Pharmaceutical Solutions Phase 3
10
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078
11
Ethanol Approved Phase 2 64-17-5 702
12
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
13
Amlodipine Approved Phase 2 88150-42-9 2162
14
Levetiracetam Approved Phase 2 102767-28-2 441341
15 Anti-Inflammatory Agents Phase 1, Phase 2
16 Psychotropic Drugs Phase 2
17 Hormone Antagonists Phase 2
18 Analgesics, Non-Narcotic Phase 2
19 Analgesics Phase 2
20 Hallucinogens Phase 2
21 Insulin, Globin Zinc Phase 2
22 insulin Phase 2
23 Gastrointestinal Agents Phase 1, Phase 2
24 Immunologic Factors Phase 1, Phase 2
25 Immunosuppressive Agents Phase 1, Phase 2
26 Autoantibodies Phase 1, Phase 2
27 Antirheumatic Agents Phase 1, Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
29 Antihypertensive Agents Phase 2
30 Hormones Phase 2
31 Vasodilator Agents Phase 2
32 Calcium, Dietary Phase 2
33 calcium channel blockers Phase 2
34 Anticonvulsants Phase 2
35
Calcium Nutraceutical Phase 2 7440-70-2 271
36
Trihexyphenidyl Approved 144-11-6, 58947-95-8 5572
37
Methylprednisolone Approved, Vet_approved 83-43-2 6741
38
Methylprednisolone hemisuccinate Approved 2921-57-5
39
Prednisolone phosphate Approved, Vet_approved 302-25-0
40
Prednisolone Approved, Vet_approved 50-24-8 5755
41 Prednisolone acetate Approved, Vet_approved 52-21-1
42
Triamcinolone Approved, Vet_approved 124-94-7 31307
43
Prednisolone hemisuccinate Experimental 2920-86-7
44
Cortisone Experimental 53-06-5 222786
45 Antiparkinson Agents
46 Muscarinic Antagonists
47 Cholinergic Antagonists
48 Dihydroxyphenylalanine
49 Methylprednisolone Acetate
50 Triamcinolone diacetate

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
2 The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial Unknown status NCT03186001 Phase 4 Abobotulinum toxin A
3 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
4 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia Completed NCT00528541 Phase 4
5 Synergistic Effects of Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
6 Pilot Study of the Effect of Botulinum Toxin Type A Treatment on Swallowing in Patients With Cervical Dystonia Completed NCT01384214 Phase 4
7 A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
8 Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia. Completed NCT00773253 Phase 4 Botulinum toxin A
9 An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia Completed NCT00702754 Phase 4
10 A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
11 Prospective, Single-arm, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 and the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Patients With Cervical Dystonia Completed NCT00541905 Phase 4 NT 201
12 An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment Completed NCT01486264 Phase 4
13 Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
14 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia Terminated NCT00432341 Phase 4
15 Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus Unknown status NCT00638066 Phase 3 botulinum toxin;botulinum toxin A
16 Prospective,Randomised, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia Completed NCT00148889 Phase 3
17 Open Multicentre Study to Demonstrate the Efficacy and Safety of Botulinum Toxin A (500 Units Dysport®) in the Treatment of Heterogeneous Forms of Cervical Dystonia Completed NCT00447772 Phase 3
18 A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Completed NCT01753310 Phase 3 Placebo
19 A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport® Using 2 mL Dilution In Adults With Cervical Dystonia Completed NCT01753336 Phase 3
20 A Prospective, Randomized, Multi-center, Phase III, Double-Blind, Activi Controlled, Parallel-group Study to Evaliate the Efficacy and Safety of MEDITOXIN® Comparison With BOTOX® in Treatment of Cervical Dystonia Completed NCT03905304 Phase 3
21 A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia Completed NCT00257660 Phase 3 Placebo
22 A Prospective, Randomized, Multi-center, Phase III, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Cervical Dystonia Completed NCT03232320 Phase 3 Meditoxin;Placebo
23 Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia Completed NCT00407030 Phase 3 incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo
24 A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3
25 Efficacy and Safety of Xeomin for the Treatment of Notalgia Paresthetica Completed NCT01098019 Phase 3 Xeomin;Placebo / Xeomin
26 A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia Completed NCT01261611 Phase 3 Placebo
27 Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study Completed NCT02604186 Phase 2, Phase 3
28 A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) Recruiting NCT03617367 Phase 3
29 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
30 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) Active, not recruiting NCT03608397 Phase 3
31 A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients Enrolling by invitation NCT03805152 Phase 3 Neuronox(R);Dysport (R)
32 ASIS for Botox in Cervical Dystonia Unknown status NCT02074293 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Botox intramuscularly at Week 6;Efficacy of Botox intramuscularly at Week 12;Efficacy of Botox intramuscularly at Week 18;Efficacy of Botox intramuscularly at Week 24;Efficacy of Botox intramuscularly at Week 30;Efficacy of Botox subdermally at Week 6;Efficacy of Botox subdermally at Week 12;Efficacy of Botox subdermally at Week 18;Efficacy of Botox subdermally at Week 24;Efficacy of Botox subdermally at Week 30;Adverse Reactions of Botox intramuscularly;Adverse Reactions of Botox subdermally
33 Phase II, Double Blind, Randomized, Placebo Controlled Trial of Dronabinol for the Treatment of Cervical Dystonia Unknown status NCT00418925 Phase 2 Dronabinol
34 Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin Unknown status NCT02867787 Phase 2 Botox arm
35 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Unknown status NCT02810015 Phase 2 Botulinum Toxin Type A
36 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
37 Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia Completed NCT02706795 Phase 2
38 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia Completed NCT00564681 Phase 2 Normal Saline
39 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis Completed NCT00165776 Phase 2 BOTULINUM TOXIN TYPE B
40 Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia Completed NCT01588574 Phase 2
41 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects Completed NCT00280384 Phase 2 E2014 (Botulinum toxin type B);E2014 (Botulinum toxin type B) Placebo
42 Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia Completed NCT00015457 Phase 2 Amlodipine plus Botulinum toxin
43 Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Botulinum Toxin Type A (Botox) for the Treatment of Pain Associated With Cervical Dystonia and Refractory Cervicothoracic Myofascial Pain Syndrome Completed NCT00178945 Phase 1, Phase 2 Botulinum Toxin Type A
44 An Open-label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel (E2007) in Subjects With Cervical Dystonia (SAFE-Per CD) Completed NCT02131467 Phase 1, Phase 2 Perampanel
45 Comparison of Clinical and Kinematic Assessment in the Determination of Botox® Injection Parameters in Cervical Dystonia Patients Active, not recruiting NCT02662530 Phase 2 Botulinum Toxin Type A
46 Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A: A Randomized Double-blind Controlled Multicenter Pilot Study Not yet recruiting NCT04426123 Phase 2 Botulinum toxin type A
47 Prospective Double Blind Evaluation of Levetiracetam (Keppra) for the Treatment of Cervical Dystonia Terminated NCT00760318 Phase 2 Keppra
48 Effectiveness of Botulinum Toxin Injection After Exercising Splenius Capitis Muscle in Patients With Cervical Dystonia Unknown status NCT01041157 Phase 1
49 A Phase I, Single-dose, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety of PurTox for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia and to Explore Dose-associated Efficacy Completed NCT00549341 Phase 1 Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
50 Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Primary Cervical Dystonia Completed NCT00132340 Phase 1

Search NIH Clinical Center for Cervical Dystonia

Genetic Tests for Cervical Dystonia

Anatomical Context for Cervical Dystonia

MalaCards organs/tissues related to Cervical Dystonia:

40
Brain, Globus Pallidus, Subthalamic Nucleus, Testes, Cortex, Cerebellum, Spinal Cord

Publications for Cervical Dystonia

Articles related to Cervical Dystonia:

(show top 50) (show all 2108)
# Title Authors PMID Year
1
Is Botulinum Toxin Type A Efficacious, Safe, and Tolerable in Cervical Dystonia?: A Cochrane Review Summary With Commentary. 61
32251106 2020
2
The efficacy of single-photon emission computed tomography in identifying dystonic muscles in cervical dystonia. 61
32404643 2020
3
The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial. 61
32521736 2020
4
Acquired Os Odentoideum Due to Cervical Dystonia in a Child With Dyskinetic Cerebral Palsy. 61
32543019 2020
5
Non-invasive brain stimulation and kinesiotherapy for treatment of focal dystonia: Instrumental analysis of three cases. 61
32284289 2020
6
Pallidal Activity in Cervical Dystonia with and Without Head Tremor. 61
32095996 2020
7
Diagnostic Delay in Cervical Dystonia: Dystonia with Antecedent Essential Tremor? 61
32562458 2020
8
Evidence for normal intracortical inhibitory recruitment properties in cervical dystonia. 61
32304844 2020
9
Reply to: Diagnostic Delay in Cervical Dystonia-Dystonia With Antecedent ET? 61
32562459 2020
10
Defective Human Motion Perception in Cervical Dystonia Correlates With Coexisting Tremor. 61
32199036 2020
11
Predictive factors of outcome in cervical dystonia following deep brain stimulation: an individual patient data meta-analysis. 61
32140866 2020
12
Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing. 61
31984559 2020
13
Low-frequency transcranial magnetic stimulation of the left dorsal premotor cortex in patients with cervical dystonia. 61
32535288 2020
14
Patient-reported responses to medical treatment in primary dystonia. 61
32249176 2020
15
Novel CACNA1A variant may cause cervical dystonia and cerebellar ataxia syndrome. 61
32480075 2020
16
NGLY1 deficiency-A rare congenital disorder of deglycosylation. 61
32395402 2020
17
Letter to the Editor, "A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia". 61
32035806 2020
18
Reply to letter to the editor, "A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia." 61
32127261 2020
19
FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. 61
32429600 2020
20
Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study. 61
31960136 2020
21
Anatomo-Functional Mapping of the Primate Mesencephalic Locomotor Region Using Stereotactic Lesions. 61
31922282 2020
22
Headache attributed to craniocervical dystonia: A prospective cohort study. 61
32422691 2020
23
Predictive factors for outcome of pallidal deep brain stimulation in cervical dystonia. 61
32036265 2020
24
A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia. 61
31938862 2020
25
Characterizing vocal tremor in progressive neurological diseases via automated acoustic analyses. 61
32146096 2020
26
Clinical Rating Scales and Quantitative Assessments of Movement Disorders. 61
32279708 2020
27
Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. 61
32332130 2020
28
Endoscopic Injection of the Longus Capiti Muscle in the Treatment of Dystonic Head Flexion. 61
32258227 2020
29
[Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) for assessment of non-motor symptoms in dystonia : Intercultural adaptation in the German language]. 61
32144450 2020
30
The effects of a laser-guided postural reeducation program on pain, neck active range of motion, and functional improvement in a 75-year-old patient with cervical dystonia. 61
29939800 2020
31
Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias. 61
32344856 2020
32
Cervical dystonia - improving the effectiveness of botulinum toxin therapy. 61
32285434 2020
33
Pallidal Deep Brain Stimulation Reduces Sensorimotor Cortex Activation in Focal/Segmental Dystonia. 61
31922299 2020
34
Mental health and quality of life in patients with cervical dystonia. 61
32318953 2020
35
Objective Analysis of Neck Muscle Boundaries for Cervical Dystonia Using Ultrasound Imaging and Deep Learning. 61
31940567 2020
36
Effect of Neck Botulinum Neurotoxin Injection on Proprioception and Somatosensory-Motor Cortical Processing in Cervical Dystonia. 61
32102606 2020
37
Pallidal 1/f asymmetry in patients with cervical dystonia. 61
32237251 2020
38
Spatial and egocentric mental rotation in patients with cervical dystonia. 61
32307583 2020
39
Hemodynamic responses are abnormal in isolated cervical dystonia. 61
31692015 2020
40
Sensory trick phenomenon in cervical dystonia: a functional MRI study. 61
31897600 2020
41
The effects of a relaxation program featuring aquatic therapy and autogenic training among people with cervical dystonia (a pilot study). 61
29939827 2020
42
Assessment of hand functions in patients with idiopathic cervical dystonia. 61
31950896 2020
43
Extending the Phenotypic Spectrum Associated with STUB1 Mutations: A Case of Dystonia. 61
32258232 2020
44
Cervical dystonia incidence and diagnostic delay in a multiethnic population. 61
31774238 2020
45
Effective botulinum toxin injection guide for treatment of cervical dystonia. 61
31301235 2020
46
Preferred muscles in cervical dystonia. 61
32227332 2020
47
Smell and taste in cervical dystonia. 61
32062706 2020
48
Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. 61
31848221 2020
49
A new treatment for cervical vertigo with botulinum toxin. 61
31956085 2020
50
Strategy for starting BoNT treatment (written consent, initial dose and subsequent doses, interval, follow-up). 61
32103794 2020

Variations for Cervical Dystonia

Expression for Cervical Dystonia

Search GEO for disease gene expression data for Cervical Dystonia.

Pathways for Cervical Dystonia

Pathways related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.32 TH DRD5
2
Show member pathways
10.26 TH SPR GCH1

GO Terms for Cervical Dystonia

Biological processes related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic transmission, dopaminergic GO:0001963 9.46 TH DRD5
2 nitric oxide biosynthetic process GO:0006809 9.43 SPR GCH1
3 cofactor metabolic process GO:0051186 9.4 SPR GCH1
4 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.37 GNAL DRD5
5 regulation of protein localization to cell surface GO:2000008 9.32 TOR1A BDNF
6 dopamine biosynthetic process GO:0042416 9.26 TH GCH1
7 regulation of resting membrane potential GO:0060075 9.16 NALCN ATP1A3
8 mating behavior GO:0007617 8.96 TH DRD5
9 tetrahydrobiopterin biosynthetic process GO:0006729 8.62 SPR GCH1

Molecular functions related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine binding GO:0035240 8.62 TH DRD5

Sources for Cervical Dystonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....